Osteoarthritis pain therapeutic - Eli Lilly
Latest Information Update: 26 Oct 2012
At a glance
- Originator Eli Lilly
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Musculoskeletal pain
Most Recent Events
- 17 Oct 2012 Discontinued - Phase-I for Musculoskeletal pain in USA (unspecified route)
- 15 Feb 2011 Phase-I clinical trials in Musculoskeletal pain in USA (unspecified route)